Read more
1:05 PM · 27 September 2024

FDA approves Bristol Myers' innovative drug for schizophrenia 💡

-
-
Open account Download free app

Bristol Myers (BMY.US) shares are up 4% ahead of the week’s final session on Wall Street after the drugmaker won approval from the U.S. Food and Drug Administration for its novel drug Cobenfa as a treatment for schizophrenia in adults. Analysts have commented that the FDA approval could help Bristol approve its acquisition of Karuna Therapeutics, which would theoretically expand BMY’s sales capabilities.

The FDA-approved drug is notable for being the first antipsychotic drug to target cholinergic receptors rather than dopamine receptors, which could be safer for patients in some situations. It is the first approved drug for schizophrenia in 30 years.

 

The stock is gaining ahead of the open and is trading well above the 200-day EMA (golden line on the chart), which could define the overall trend in the stock over the long term. Source: xStatio

4 February 2026, 4:10 PM

India: New battleground of the trade war?

4 February 2026, 3:23 PM

BREAKING🚨US100 decline extends amid inflationary ISM report and tech stocks sell-off

4 February 2026, 2:36 PM

Alphabet Q4 2025 preview. Is the pace of AI monetization sustainable?

4 February 2026, 1:58 PM

Market wrap🚨 European stocks outpace Wall Street📈Nasdaq sell-off to continue?

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits